Helus Pharma falls 10.5% despite positive HLP003 trial
Helus Pharma (HELP) reported positive results for its experimental drug HLP003, meeting the primary endpoint in a late-stage depression trial. Despite this, shares fell 10.5% to $7.94, with three serious adverse events disclosed. Analysts noted strong efficacy and no fundamental reason for the decline. The company is also developing HLP004 for anxiety and expects to identify an HLP005 candidate in late 2027.
How this was made

The 30-second read
Why it matters
The primary endpoint success is offset by disclosure of three serious adverse events considered related to treatment, including a suicide attempt in a non-responder, driving a sharp selloff on the news.
Market read
This is a same-day catalyst for HELP, combining efficacy success with serious safety disclosures that can materially change perceived clinical risk and future trial design expectations.
What to watch
Traders may be underweighting the trial’s placebo-adjusted improvement magnitude and the company’s continued pipeline timelines (HLP004 Phase 2 start in 1Q 2027, HLP005 candidate in 2H 2027) when extrapolating near-term risk.
Background
Helus Pharma is developing psychedelic candidates HLP003 for depression, with additional programs HLP004 (generalized anxiety disorder) and HLP005 planned for later-stage development.
Ticker impact
Helus Pharma reported HLP003 met the primary endpoint in a late-stage depression trial but also disclosed three serious treatment-related adverse events, including a suicide attempt.
Likely continued downside pressure as traders weigh safety risk against efficacy and reassess probability of future development success.
The article ties the same announcement to a sharp -10.5% move and highlights a serious adverse event related to treatment, which typically dominates near-term biotech risk pricing.
Market effects
Reinforces that efficacy wins in psychedelic depression programs may still face heavy valuation discounts when serious safety signals emerge.
US-listed biotech sentiment likely pressured in the near term as investors reprice clinical risk across development-stage CNS names.
Limited direct global spillover, but safety-focused read-through can affect international investor appetite for psychedelic CNS trials.
Counterpoint
Analyst commentary in the article suggests the efficacy result was very strong and that a single adverse case may not establish a broader safety signal.
Key entities
- companyHelus Pharma
NASDAQ-listed developer of psychedelic drug candidates, including HLP003 for depression.
- clinical_programHLP003
Experimental psychedelic drug tested in a late-stage depression trial; met the primary endpoint but with serious treatment-related adverse events reported.
- clinical_programHLP004
Program for generalized anxiety disorder, previously targeted to start Phase 2 in 1Q 2027.
- clinical_programHLP005
Planned development candidate identification in 2H 2027 as the pipeline advances.




